153 related articles for article (PubMed ID: 38432446)
1. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.
Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
[TBL] [Abstract][Full Text] [Related]
2. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages.
Zhu M; Bai L; Liu X; Peng S; Xie Y; Bai H; Yu H; Wang X; Yuan P; Ma R; Lin J; Wu L; Huang M; Li Y; Luo Y
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600555
[TBL] [Abstract][Full Text] [Related]
3. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1.
Chen TW; Hung WZ; Chiang SF; Chen WT; Ke TW; Liang JA; Huang CY; Yang PC; Huang KC; Chao KSC
Cancer Lett; 2022 Sep; 543():215795. PubMed ID: 35718267
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy.
Lv Q; Yang H; Wang D; Zhou H; Wang J; Zhang Y; Wu D; Xie Y; Lv Y; Hu L; Wang J
J Med Chem; 2024 Apr; 67(8):6854-6879. PubMed ID: 38593344
[TBL] [Abstract][Full Text] [Related]
6. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
8. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
9. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
10. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer-Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD-L1 Expression in Tumor-Associated Macrophages.
Yin Y; Liu B; Cao Y; Yao S; Liu Y; Jin G; Qin Y; Chen Y; Cui K; Zhou L; Bian Z; Fei B; Huang S; Huang Z
Adv Sci (Weinh); 2022 Mar; 9(9):2102620. PubMed ID: 35356153
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy.
Cheruku S; Rao V; Pandey R; Rao Chamallamudi M; Velayutham R; Kumar N
Int Immunopharmacol; 2023 Mar; 116():109569. PubMed ID: 36773572
[TBL] [Abstract][Full Text] [Related]
13. Modulation of miR-146b by N6-methyladenosine modification remodels tumor-associated macrophages and enhances anti-PD-1 therapy in colorectal cancer.
He S; Song W; Cui S; Li J; Jiang Y; Chen X; Peng L
Cell Oncol (Dordr); 2023 Dec; 46(6):1731-1746. PubMed ID: 37402945
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
[TBL] [Abstract][Full Text] [Related]
15. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer.
Min AKT; Mimura K; Nakajima S; Okayama H; Saito K; Sakamoto W; Fujita S; Endo H; Saito M; Saze Z; Momma T; Ohki S; Kono K
Cancer Immunol Immunother; 2021 Feb; 70(2):289-298. PubMed ID: 32705303
[TBL] [Abstract][Full Text] [Related]
17. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
18. Salvia mitiorrhiza Bunge aqueous extract attenuates infiltration of tumor-associated macrophages and potentiates anti-PD-L1 immunotherapy in colorectal cancer through modulating Cox2/PGE2 cascade.
Song M; Qian C; Zhang T; Tang Y; Zhou Y; Wei Z; Wang A; Zhong C; Zhao Y; Lu Y
J Ethnopharmacol; 2023 Nov; 316():116735. PubMed ID: 37286115
[TBL] [Abstract][Full Text] [Related]
19. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.
Magkouta SF; Vaitsi PC; Pappas AG; Iliopoulou M; Kosti CN; Psarra K; Kalomenidis IT
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067348
[TBL] [Abstract][Full Text] [Related]
20. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Gyori D; Lim EL; Grant FM; Spensberger D; Roychoudhuri R; Shuttleworth SJ; Okkenhaug K; Stephens LR; Hawkins PT
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
